Fundraising FoxKronos Bio
AcquiredNew York, US · Founded 2017 · Delaware corporation · 15 known investors
Find your way into Kronos Bio
Sign up to see every warm intro you have to Kronos Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kronos Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Concentra Biosciences May 2025 · terms undisclosed — $0.57 in cash per share plus one non-tradeable contingent value right (CVR) · source ↗
Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
Founders & leadership
Board
Investors · 15
How we know: GV (Google Ventures)'s portfolio page · medcitynews.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Nextech Invest's portfolio page · a partner's Signal profile · medcitynews.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vida Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · medcitynews.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: medcitynews.com · Not right? Tell us
How we know: medcitynews.com · Not right? Tell us
How we know: medcitynews.com · Not right? Tell us
How we know: medcitynews.com · Not right? Tell us
Also in the syndicate · 6
Reported raises · per SEC filings
Form D private placements$123M disclosed across 2 of 4 rounds · 2018–2020
▶$105MraisedJul 2019 · 50 investors · BiotechnologyRule 506(b)
- Jacob LovenDirector
- Rebecka Belldegrun, M.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- John C. Martin, Ph.D.Director
- Philip GutryExecutive Officer
- David M. TanenExecutive Officer, Director, Promoter
- Sean AlgeoExecutive Officer
- Joshua A. KazamDirector
- Otello Stampacchia, Ph.D.Director
- Arie S. Belldegrun, M.D.Director
- Offering amount
- $105M
- Amount sold
- $105M
- Proceeds to insiders
- $360K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$18MraisedJun 2018 · 32 investors · BiotechnologyRule 506(b)
- Rebecka Belldegrun, M.D.Director
- Otello Stampacchia, Ph.D.Director
- David M. TanenExecutive Officer, Director, Promoter
- John C. Martin, Ph.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- Arie S. Belldegrun, M.D.Director
- Christopher WilfongExecutive Officer
- Joshua A. KazamDirector
- Offering amount
- $18M
- Amount sold
- $18M
- Proceeds to insiders
- $360K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Kronos Bio went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Kronos Bio.
In the news
Frequently asked questions
- What does Kronos Bio do?
- Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
- Who are Kronos Bio's investors?
- Kronos Bio's investors include EcoR1 Capital, GV (Google Ventures), Nextech Invest, Vida Ventures, BlackRock, Commodore Capital, Invus, Omega Funds and 1 more.
- How much funding has Kronos Bio raised?
- Kronos Bio has disclosed $123M raised across 2 of its 4 known rounds.
- Where is Kronos Bio headquartered?
- Kronos Bio is headquartered in New York, US.